Nowadays, Magnolol has become an increasingly recurring topic of conversation in society. With the advancement of technology and globalization, Magnolol has acquired a leading role in our lives, significantly impacting different aspects. From economics to culture, Magnolol has left an indelible mark on the contemporary world. For this reason, it is important to analyze and reflect on Magnolol, understanding its implications and consequences in our current reality. In this article, we will explore in depth the impact of Magnolol and its relevance in modern society.
Names | |
---|---|
IUPAC name
3,3′-Neoligna-8,8′-diene-4,4′-diol
| |
Systematic IUPAC name
5,5′-Di(prop-2-en-1-yl)-2,2′-diol | |
Other names
Dehydrodichavicol
5,5'-Diallyl-2,2'-dihydroxybiphenyl 5,5'-Diallyl-2,2'-biphenyldiol | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.127.908 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C18H18O2 | |
Molar mass | 266.340 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
Magnolol is an organic compound that is classified as lignan. It is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis) and in M. grandiflora. The compound exists at the level of a few percent in the bark of species of magnolia, the extracts of which have been used in traditional Chinese and Japanese medicine. In addition to magnolol, related lignans occur in the extracts including honokiol, which is an isomer of magnolol.
It is known to act on the GABAA receptors in rat cells in vitro as well as having antifungal properties. Magnolol has a number of osteoblast-stimulating and osteoclast-inhibiting activities in cell culture and has been suggested as a candidate for screening for anti-osteoporosis activity. It has anti-periodontal disease activity in a rat model. Structural analogues have been studied and found to be strong allosteric modulators of GABAA.
Magnolol is also binding in dimeric mode to PPARγ, acting as an agonist of this nuclear receptor.
Magnolol may interact with cannabinoid receptors, acting as a partial agonist of CB2 receptors, with lower affinity for the CB1 receptor.